Generic MS Drug Development Was Protected, Sandoz Says

Law360, New York (April 18, 2013, 8:45 PM EDT) -- Sandoz Inc. asked a New York federal judge Wednesday to toss Teva Pharmaceuticals Industries Ltd.'s patent infringement suit, saying its use of a patented process as it developed a generic form of multiple sclerosis drug Copaxone was protected by the safe harbor exemption.

Teva sued Sandoz in December 2009 for using the polypeptide TP-116 in its preparation of generic glatiramer acetate — thereby allegedly infringing on four Teva patents — but Sandoz said Wednesday that it was allowed to use the chemical compound under the research...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.